So... Richard just said above (back in 2019) that the MPL target market that PAA/Elanco aim to achieve (for B-cell Lymphoma cancer in canines) is roughly between
$1B and $4BILLION DOLLARS...
I know this may have been previously calculated in these threads, but it needs to be mentioned again...
I guess a 10% cut is pretty easy to work out
But who knows how big this deal could end up...
We can only adreamer...
Ann: Final Report delivered under Option Agreement, page-156
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.005(2.22%) |
Mkt cap ! $100.1M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 22.0¢ | $42.74K | 192.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 67 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 161984 | 5 |
View Market Depth
| Last trade - 12.53pm 17/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |